August 2026 Research Update

Across the treatment-focused reports this month, complement-blocking medicines were linked with fast improvement in blood counts and kidney recovery in a few individual patients with complement-mediated thrombotic microangiopathy, especially when standard supportive approaches had not worked. These are not trials, but they add concrete real-world examples of how quickly some people can stabilize once the complement pathway is targeted. A separate small case series suggested that looking for an "mTOR on" signal in a kidney biopsy might help identify some patients (including one with aHUS/TMA) who could have stable or improved kidney outcomes on sirolimus, though the group was very small and mixed. [1] [2] [3] [4]

In one pediatric aHUS report triggered by influenza A(H1N1), ravulizumab (a long-acting C5 blocker) was followed by rapid normalization of blood measures and full kidney recovery by day 106 after plasma exchange and dialysis had not helped. [1]

In a postpartum recurrent aHUS case linked to a C3 gene variant, eculizumab (a C5 blocker) alongside supportive kidney care was followed by complete kidney and blood remission within 4 weeks, with remission reported as stable at 7 months while continuing therapy. This adds another example where pregnancy-related timing and complement genetics were central to understanding the episode. [2]

In an older adult with anti-GBM antibody kidney disease complicated by refractory complement-mediated TMA, a CD46 genetic variant was identified and eculizumab was followed by transfusion independence within 1 week. This report does not prove what would happen for others, but it shows how complement-mediated TMA can appear alongside other kidney immune diseases and still respond after other treatments. [3]

A proof-of-concept case series used kidney biopsy staining to look for signs that the mTOR pathway was activated, then treated the biopsy-positive group with sirolimus (an mTOR blocker). Four of 5 patients had stable or improved kidney function with lower protein in the urine, while one patient with weak staining progressed to kidney failure; one of the included diagnoses was described as aHUS/TMA. Because the conditions and background treatments differed across patients, this mainly supports the idea that biopsy signals might one day help match treatments to biology. [4]

For patients and caregivers, these studies mainly add practical context rather than new rules for care. The complement-blocking case reports (eculizumab or ravulizumab) describe rapid blood improvement and, in some cases, kidney recovery in specific situations like infection-triggered aHUS, postpartum recurrence, or TMA complicating another kidney immune disease, but single-patient reports cannot predict what will happen for someone else. The sirolimus series is early research that raises a future possibility: a kidney biopsy signal might help identify who is more likely to have stable kidney outcomes on an mTOR-targeting drug, but it needs confirmation in larger, more uniform groups. [1] [2] [3] [4]

This month strengthened the picture that "TMA" is not one disease, and that the cause and severity at the start strongly shape longer-term outcomes. A large pediatric cohort showed that secondary TMA (often after stem cell transplant) and signs of severe illness such as shock or needing a breathing machine were linked with higher risk of death or progression to kidney failure over time. Smaller studies focused on ways to track complement-related injury, including complement activation markers in stem cell transplant TMA and a blood test used after kidney transplant that behaved differently in 2 recipients with aHUS. [5] [6] [7]

In the 9-year pediatric cohort of 303 first-episode TMA cases, secondary TMA was the most common category and had more frequent death or progression to kidney failure than other causes, including aHUS. The study also found that heart failure or shock at onset and the need for mechanical ventilation were independent predictors of worse outcomes, highlighting how the early course of illness can signal longer-term risk. [5]

A clinical biomarker study focusing on stem cell transplant-related TMA reported that Ba (a complement activation marker) performed well as a predictor of TMA onset, and that complement activation was more often elevated postpartum than during pregnancy. This supports the idea that measuring complement activation may help identify higher-risk periods or earlier disease activity in certain settings, but the summary did not include sample size or detailed performance numbers. [6]

In a small kidney transplant dataset, donor-derived cell-free DNA (dd-cfDNA) steadily declined over 2 months in recipients without aHUS, while the 2 recipients with aHUS had values near or above 1% through month 1 before declining by month 2. No donor-specific antibodies or clinically documented rejection were detected, so the higher early dd-cfDNA in the aHUS recipients remains an observation rather than an explanation, and it needs confirmation with larger numbers and more systematic biopsies. [7]

For patients, this group of studies helps clarify two different questions: prognosis in broad "TMA" and monitoring in specific situations. The pediatric cohort suggests that the underlying cause (especially secondary TMA) and how sick someone is at the start (shock or needing ventilation) can be warning signs for higher long-term risk, which may matter for future research on follow-up planning and supportive needs. The biomarker reports (Ba, sC5b-9, and dd-cfDNA after transplant) are still exploratory and do not establish a single test that reliably diagnoses or predicts aHUS for everyone, but they add momentum to the idea that blood markers could help detect complement-related injury earlier in certain high-risk settings. [5] [6] [7]

This month added several pieces that try to separate what is cause, what is consequence, and what is measurable in aHUS. One aHUS cohort study found Factor XIII changes during acute illness and remission but did not find rare Factor XIII gene variants enriched in aHUS, arguing against Factor XIII being a main genetic driver while still raising a possible biomarker signal. In parallel, a data-science study pooled public data across multiple diseases to estimate what eculizumab blood levels correspond to complete C5 blockade, and two case reports emphasized how complement gene variants can strongly shape risk discussions and mechanistic understanding. [8] [9] [10] [11] [12]

In a study of 102 people with aHUS and 73 healthy controls, Factor XIII activity and the FXIII-A subunit were lower in the 36 patients tested during the acute phase and closer to normal in remission, while free FXIII-B was higher in remission than in controls. Genetic screening of Factor XIII genes did not show an enrichment of rare variants in aHUS, which makes a direct inherited Factor XIII cause less likely in this cohort, even though the blood patterns could still be useful to study as markers of disease state. [8]

A pooled analysis across several complement-mediated diseases used public clinical data to model whether eculizumab blood concentration predicts complete C5 inhibition, and it reported an estimate around 310 to 335 microg/mL for the concentration where inhibition becomes likely. The authors also showed that adding carefully generated synthetic data narrowed the uncertainty around that estimate, but they emphasized that prospective validation is needed before this kind of modeling is used in real patient decisions. [9]

A case report in a child with spinal muscular atrophy described undetectable C3 on baseline testing and C3 and CFI gene variants found on sequencing, which led the treating team to withhold a planned gene therapy due to concern for TMA risk. This single case highlights that complement testing can affect eligibility discussions for non-aHUS treatments when a complement risk profile is uncovered. [10]

A separate aHUS case with a homozygous THBD mutation combined clinical findings with lab and animal modeling, showing the mutant thrombomodulin protein was mostly absent from the cell surface and disrupted other endothelial (blood vessel lining) proteins. This helps make the biology more tangible: in at least one genetic form of aHUS, the vessel lining itself may be unusually fragile or dysregulated, which can connect bleeding and clotting problems to the same underlying defect. [11]

A review paper discussed complement and clotting system interactions and noted that Japanese aHUS patients often have a specific gain-of-function C3 variant (p.Ile1157Thr), with favorable outcomes reported despite relapses. As a review, it does not provide new patient-level results this month, but it reinforces that aHUS genetics can vary by population and may connect to different long-term patterns. [12]

For patients and caregivers, these studies mostly add to understanding and measurement rather than offering immediate changes in care. The Factor XIII work suggests some blood proteins involved in clot stabilization shift between acute aHUS and remission, but it also argues that inherited Factor XIII gene changes are unlikely to be a common root cause, which helps narrow the search for drivers of aHUS. The eculizumab modeling work is early and does not set a target level for individuals, but it shows active research interest in more precise ways to confirm "complete complement blockade". The genetic case reports underline that specific complement or endothelial gene variants can meaningfully shape risk discussions and may explain why aHUS can look different from person to person, while still being too limited to generalize from any single patient. [8] [9] [10] [11] [12]